SKIN CANCERS

General Cancer

Genetic aberrations across cancer types were the driving force behind drug approvals in 2018.

Nikhil I. Khushalani, MD,&nbsp;discusses the role of adjuvant therapy in patients with melanoma across various subtypes, and also highlights melanoma trials ongoing at Moffitt Cancer Center.<br /> &nbsp;

Jeffrey Weber, MD, PhD, discussed the data in support of discontinuing treatment in melanoma and how to properly follow these patients after they go off treatment.<br /> &nbsp;

Robert Andtbacka, MD,&nbsp;discusses the current use of T-VEC in melanoma and future directions with this type of treatment.

Pembrolizumab has been granted an&nbsp;accelerated approval by the FDA as a treatment for&nbsp;adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma.

Precision medicine has produced some dramatic successes in patients with advanced cancer. With developments in molecular profiling, targeted therapies are being applied to multiple tumors, most notably in advanced melanoma, NSCLC, and several types of leukemia. Alison Schram, MD, and David M. Hyman, MD, point out the challenges in determining the proportion of patients who will benefit from receiving targeted therapies.

Danny Rischin, MD, MBBS,&nbsp;discusses the phase II activity with cemiplimab as a novel PD-1 inhibitor for patients with metastatic and locally advanced CSCC.

Patients with advanced basal cell carcinoma who experience progression on hedgehog pathway inhibitor therapy, or are intolerant to it, have no approved therapeutic options. An ongoing phase II study evaluating cemiplimab in this population may prove efficacious based on its activity in other advanced malignancies.

Findings of an&nbsp;analysis of patient-reported outcomes with avelumab in the JAVELIN Merkel 200 trial showed consistency of effectiveness in patients with&nbsp;metastatic Merkel cell carcinoma based on clinical and PRO endpoints.

Management of a Patient With a Very Large Ocular CSCC Tumor

A phase II trial is currently recruiting patients with Merkel cell carcinoma to participate in a single-arm study evaluating the safety and efficacy of INCMGA00012.¹The open-label, multicenter study seeks to enroll 90 patients, including at least 52 patients who are treatment-na&iuml;ve. In addition, only 40 patients who are chemotherapy-refractory will be allowed to participate

Cabozantinib demonstrated the strongest response observed to date among all the multikinase inhibitors that have shown activity in bone sarcoma, according to results from the CABONE trial that were reported at the 2018 CTOS Annual Meeting.

Danny Rischin, MD, MBBS, FRACP, discusses an ongoing phase III trial for patients with metastatic cutaneous squamous cell carcinoma or recurrent disease after progressing on frontline chemotherapy.&nbsp;